¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Ehrlich's triple stain"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • negative stain
    À½¼º¿°»ö
  • neutral stain
    Áß¼º¿°»ö
  • Nissl stain
    ´Ï½½¿°»ö
  • nuclear stain
    ÇÙ¿°»ö
  • port-wine stain
    Æ÷µµÁÖ»ö¹ÝÁ¡
  • periodic acid-Schiff stain
    PAS¿°»ö
  • permanent stain
    ¿µ±¸¿°»ö
  • spore stain
    ¾ÆÆ÷¿°»ö
  • stain
    1. ¿°»ö 2. ¿°·á 3. ¾ó·è
  • supravital stain
    ÃÊ»ýü¿°»ö
  • selective stain
    ¼±Åÿ°»ö
  • silver stain
    Àº¿°»ö
  • simple stain
    ´Ü¼ø¿°»ö
  • Weigert stain
    1. ¹ÙÀ̰Ը£Æ®¿°»ö 2. ¹ÙÀ̰Ը£Æ®¿°·á
  • Ziehl-Neelsen stain
    Ä¥-³Ú¼¾¿°»ö
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Gram stain
    ±×¶÷¿°»ö
  • heavy-metal stain
    Á߱ݼӿ°»ö
  • histochemical stain
    Á¶Á÷È­Çп°»ö
  • intravital stain
    »ýü¿°»ö
  • marrow iron stain
    °ñ¼öö¿°»ö
  • metachromatic stain
    ÀÌ¿°»ö¿°·á, µÐ°©¿°»ö
  • metallic stain
    ±Ý¼Ó¿°»ö
  • mucin stain
    Á¡¾×¿°»ö
  • nuclear stain
    ÇÙ¿°»ö
  • periodic acid-Schiff stain
    ÇÇ¿¡ÀÌ¿¡½º¿°»ö
  • permanent stain
    ¿µ±¸¿°»ö
  • port-wine stain
    Æ÷µµÁÖ»ö¹ÝÁ¡
  • stain
    ¿°»ö, ¿°·á, Âø»ö
  • selective stain
    ¼±Åÿ°»ö
  • seminal stain
    Á¤¾×¹Ý, Á¤¾×ÈçÀû
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Wheatley trichrome stain
    À§Æ²¸®Æ®¸®Å©·Ò¿°»ö
  • Wright stain
    ¶óÀÌÆ®¿°»ö
  • Ziehl Neelsen stain
    Áú-´ÏÀϼ¾¿°»ö.
  • Ziehl-Neelsen stain
    ÂîÀÏ-´Ò¼¾¿°»ö
  • acid fast stain
    Ç×»ê(¼º) ¿°»ö(¡­æøßä).
  • acid-fast stain
    Ç׻꼺 ¿°»ö
  • acid-fast stain
    Ç׻꼺¿°»ö(ù÷ß«àõæøßä)
  • acridine orange stain
    ¾ÆÅ©¸®µò¿À·»Áö¿°»ö
  • giemsa stain
    ±èÀÚ¿°»ö
  • gram stain
    ±×·¥¿°»ö
  • histochemical stain
    Á¶Á÷ È­ÇÐ ¿°»ö
  • histochemical stain
    Á¶Á÷È­Çп°»ö
  • plasmatic stain =plasmic s.
    ¿øÇüÁú¿°»ö¾×(ê«û¡òõæøßääû)
  • port-wine stain
    Ç÷°ü¸ð¹Ý(úìηٽÚè), Æ÷µµÁÖ»ö¸ð¹Ý(øãÔ¬ñÐßäÙ½Úè)
  • port-wine stain = nevus flammeus
    ºÒ²É¸ð¹Ý
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • triple response
    »ïÁß¹ÝÀÀ(ß²ñìÚãëë)
  • triple rhythm
    »ïÁßÀ²µ¿(ß²ñìëÏÔÑ).
  • triple skin reaction
    »ïÁßÇǺιÝÀÀ(ß²ñìù«Ý±Úãëë).
  • triple skin reaction
    »ïÁßÇǺιÝÀÀ(ß²ñìù«Ý±Úãëë)
  • triple sugar iron (TSI) agar
    »ï´çûºÐ¹èÁö, TSI Àå³»¼¼±Õµ¿Á¤¹èÁö
  • triple sugar iron agar
    »ï´çöÇÑõ
  • triple union
    »ïÁß°áÇÕ(¡­Ì¿ùê).
  • triple vaccine
    »ïÁ¾(È¥ÇÕ)(ß²ðúûèùê)¹é½Å.
  • triple vessel disease
    »ïÇ÷°üÁúȯ
  • triple x female
    »ïÁßX¿©¼º
  • triple x syndrome
    »ïÁßXÁõÈıºß²ñì¡­ñøý¦ÏØ)
  • acid fast stain
    Ç×»ê(¼º) ¿°»ö(¡­æøßä).
  • acid-fast stain
    Ç׻꼺 ¿°»ö
  • acid-fast stain
    Ç׻꼺¿°»ö(ù÷ß«àõæøßä)
  • acridine orange stain
    ¾ÆÅ©¸®µò¿À·»Áö¿°»ö
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
EATC Ehrlich ascites tumor cell
EU Ehrlich unit; elementary unit; emergency unit; endotoxin unit; entropy unit; enzyme unit; esterase u...
TSI   1) Thyroid Stimulating Immunoglobulin
  2) Triple Sugar Iron agar
FACIT fibril-associated collagen with interrupted triple helices
TCABG triple coronary artery bypass graft
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
TEW Triple Energy Window
TFO triple helix-forming oligonucleotide
TVD Triple vessel disease
TGB triple gene block
TN triple negative
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • silver stain
    Àº ¿°»ö
  • simple stain
    ´Ü¼ø ¿°»ö
  • Smith-Pitfield stain
    ½º¹Ìµå-ÇÇÆ®ÇÇÀÏµå ¿°»ö¹ý
    Æí¸ðÀÇ ¿°»ö¹ýÀ¸·Î¼­, ¸Å¿° Àç·á´Â ¾Ï¸ð´Ï¾Æ ¸í¹ÝÀÇ Æ÷È­¾×°ú ½ÂÈ« Æ÷È­¾×À» È¥ÇÕÇÑ °Í¿¡ µî·®ÀÇ 10% ź´Ñ»ê¾×°ú ¹Ý·®ÀÇ 5% Ä«¸£º¼ÇªÅ©½Å ¾×À» ³Ö¾î¼­ ¸¸µé°í, À̰ÍÀ¸·Î ¸Å¿°ÇÑ ÈÄ Á¨Æ¼¾Æ´ÏÀÚ Æ÷È­ ¾ËÄÚ¿Ã ¿ë¾× 1¿ë°ú ¾Ï¸ð´Ï¾Æ ¸í¹Ý Æ÷È­¾× 10¿ëÀÇ ¿°»ö¾×À¸·Î ó¸®ÇÑ´Ù.
  • stain
    Âø»öÁ¦, ¹°°¨, ¿°·á, Âø»öÇÏ´Ù
    »öÀ¸·Î µÚµ¤´Ù. »öÀÌ È­ÇÐÀûÀ¸·Î³ª ¹°Áú ÀÚü¿¡ ÀÇÇØ ¿µÇâÀ» ¹ÌÄ¡´Â °úÁ¤.
  • supravital stain
    ÃÊ»ýü ¿°·á
    ÀÌ¹Ì »ýü¿¡¼­ Á¦°ÅÇÑ ¼¼Æ÷ÀÇ ¸Åü¿¡ ¿°·á¸¦ °¡ÇÏ´Â ¿°»ö ¹æ¹ý.
  • tumor stain
    Á¾¾ç ¿°»ö, Á¾¾ç Á¶¿µ
  • Zettnow's stain ¼¼±Õ Æí¸ð¸¦ ¿°»öÇÏ´Â ¹æ¹ý

    Zeune's law ¸ÍÀÎÀÇ ¼ö´Â Àûµµ¿¡ °¡±î¿î ¿­´ëÁö¹æ¿¡¼­ Áõ°¡ÇÑ´Ù.

    zidovudin

    ÁöµµºÎµò
    µ¿ÀǾî=azidothymidine.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
triple vision Visual defect in which three images of the same object are seen.
Synonym: triple vision.
Origin: G. Triploos, triple, + opsis, sight
(05 Mar 2000)
triple X syndrome <syndrome> In principle, the phenotypic features characteristic of trisomy of the X chromosome. Original observations (made in mental institutions) were seriously biased and the phenotypic changes spurious; now, even the remaining claim, that there is mild mental retardation, is suspect. The outstanding feature of the syndrome is the occurence of twin Barr bodies in a typical cell.
(05 Mar 2000)
carcinoma, ehrlich tumour A transplantable, poorly differentiated malignant tumour which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms.
(12 Dec 1998)
Paul Ehrlich <person> A brilliant scientist and student, born in Silesia, Germany, who at the age of 23 published his first scientific paper which was on the discovery of the mast cells - a name coined by him (1887). While a resident in medicine at Charite Hospital in Berlin he utilised the newly discovered aniline dyes to develop some of the basic methods of histology.
Among his contributions are: The preparation and staining of blood smears, he demonstrated granules in leukocytes, described the neutrophil, basophil, eosinophil, myelocyte, and mononuclear cells (white blood cells), he demonstrated normoblasts, megaloblasts and microblasts of the erythrocytic (red blood cell) series.
In 1887, he differentiated lymphocytic leukaemia from "bone marrow leukaemia" (myeloid) on blood smear, in 1888, he described aplastic anaemia, in 1882 the diazo reaction of typhoid urines, in 1882, less than six weeks after Koch described the Tuberculus bacillus, Ehrlich had described its acid-fastness and devised the fuchsin stain to demonstrate the pink rod on a blue background.
Ehrlich fell ill with tuberculosis and went to Egypt for 3 years for rest and cure. Following his return, he entered the field of immunology. at Von Behring's request, he developed means of standardising antitoxin dosage (immunization units).
at the age of 42, he became director of the "Royal Institute for Standardisation and Investigation of Antitoxic Sera." Here he devised his famous "side-chain" theory of immunisation. It has since been replaced.
Paul Ehrlich reinvestigated Bordet's alexin and heat-stable substance and named them "complement" and "immune body". Ehrlich coined the terms and created a new science of chemotherapy.
In 1910 he discovered Salvarsan or 606, a therapeutic antiluetic. For his silver bullet (Salvarsan) in 1908, he received the Nobel Prize. This scientist was greatly concerned over the problem of drug fastness which still remains a problem. He died August 20, 1915.
Lived: 1854-1915.
(18 Nov 1997)
Heinz-Ehrlich body A round oxyphil body found in the red blood cell in case of haemocytolysis due to a specific blood poison.
Synonym: Heinz-Ehrlich body.
(05 Mar 2000)
Ehrlich Paul, German bacteriologist, immunologist, and Nobel laureate, 1854-1915.
See: Ehrlichia, Ehrlich's anaemia, Ehrlich's inner body, Ehrlich's phenomenon, Ehrlich's postulate, Ehrlich's diazo reagent, Ehrlich's theory, Ehrlich-Turk line. See entries under stain; reaction.
(05 Mar 2000)
Ehrlich, Paul <person> A brilliant scientist and student, born in Silesia, Germany, who at the age of 23 published his first scientific paper which was on the discovery of the mast cells - a name coined by him (1887). While a resident in medicine at Charite Hospital in Berlin he utilised the newly discovered aniline dyes to develop some of the basic methods of histology.
Among his contributions are: The preparation and staining of blood smears, he demonstrated granules in leukocytes, described the neutrophil, basophil, eosinophil, myelocyte, and mononuclear cells (white blood cells), he demonstrated normoblasts, megaloblasts and microblasts of the erythrocytic (red blood cell) series.
In 1887, he differentiated lymphocytic leukaemia from "bone marrow leukaemia" (myeloid) on blood smear, in 1888, he described aplastic anaemia, in 1882 the diazo reaction of typhoid urines, in 1882, less than six weeks after Koch described the Tuberculus bacillus, Ehrlich had described its acid-fastness and devised the fuchsin stain to demonstrate the pink rod on a blue background.
Ehrlich fell ill with tuberculosis and went to Egypt for 3 years for rest and cure. Following his return, he entered the field of immunology. at Von Behring's request, he developed means of standardising antitoxin dosage (immunization units).
at the age of 42, he became director of the "Royal Institute for Standardisation and Investigation of Antitoxic Sera." Here he devised his famous "side-chain" theory of immunisation. It has since been replaced.
Paul Ehrlich reinvestigated Bordet's alexin and heat-stable substance and named them "complement" and "immune body". Ehrlich coined the terms and created a new science of chemotherapy.
In 1910 he discovered Salvarsan or 606, a therapeutic antiluetic. For his silver bullet (Salvarsan) in 1908, he received the Nobel Prize. This scientist was greatly concerned over the problem of drug fastness which still remains a problem. He died August 20, 1915.
Lived: 1854-1915.
(18 Nov 1997)
Ehrlich reaction The reaction of the indole derivatives with aromatic aldehydes; e.g., tryptophan and p-dimethylaminobenzaldehyde in H2SO4 give a red-violet colour useful in assaying proteins for tryptophan content.
Synonym: Ehrlich reaction.
(05 Mar 2000)
Ehrlich's anaemia <haematology> This form of anaemia occurs when the bone marrow ceases sufficient red and white blood cell production. It may be induced by exposures to high levels of toxic chemicals, radiation and certain drugs.
It is generally unresponsive to specific therapy, often accompanied by granulocytopenia and thrombocytopenia, in which the bone marrow may not necessarily be hypocellular or hypoplastic but fails to produce adequate numbers of peripheral blood elements. The term actually is all inclusive and most probably encompasses several clinical syndromes.
Origin: Gr. Haima = blood
(29 Sep 1997)
Ehrlich's benzaldehyde reaction A test for urobilinogen in the urine, by dissolving 2 g of dimethyl-p-aminobenzaldehyde in 100 ml of 5% hydrochloric acid and adding this reagent to urine; a red colour in the cold indicates the presence of an excessive amount of urobilinogen.
(05 Mar 2000)
Ehrlich's diazo reaction The reaction of diazotised sulfanilic acid with bilirubin to form azobilirubin, which forms the basis of quantitating the amount of bilirubin in biological fluids.
See: van den Bergh's test.
Synonym: Ehrlich's diazo reaction.
(05 Mar 2000)
Ehrlich's diazo reagent Two solutions, one of sodium nitrite, the other of acidified sulfanilic acid, used in bringing about diazotization.
Synonym: Ehrlich's diazo reagent.
(05 Mar 2000)
Ehrlich's inner body A round oxyphil body found in the red blood cell in case of haemocytolysis due to a specific blood poison.
Synonym: Heinz-Ehrlich body.
(05 Mar 2000)
Ehrlich's phenomenon The difference between the amount of diphtheria toxin that will exactly neutralise one unit of antitoxin and that which, added to one unit of antitoxin, will leave one lethal dose free is greater than one lethal dose of toxin; i.e., it is necessary to add more than one lethal dose of toxin to a neutral mixture of toxin and antitoxin to make the mixture lethal (the basis of the L+ dose).
(05 Mar 2000)
Ehrlich's postulate Ehrlich postulated that cells contained surface extensions or side chains (haptophores) that bind to the antigenic determinants of a toxin (toxophores); after a cell is stimulated, the haptophores are released into the circulation and become the antibodies.
See: receptor.
Synonym: Ehrlich's postulate.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á